{
  "docId": "019de074-ead2-732b-8415-93449fe93e32",
  "docSlug": "9cc66a7a8f583a45c6978147aa12db97",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 95 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 95,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "villain_critique",
  "function": "diagnose_problem",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide focuses on criticizing the specific clinical trial strategy of the company's leadership (Barrow).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ead2-732b-8415-93449fe93e32/34",
  "deckHref": "/decks/019de074-ead2-732b-8415-93449fe93e32",
  "deckJsonHref": "/decks/019de074-ead2-732b-8415-93449fe93e32.json",
  "deckAnchorHref": "/decks/019de074-ead2-732b-8415-93449fe93e32#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.21,
        "y": 0.2
      },
      "kind": "list",
      "text": "Even if a Phase IIb were needed, we believe MindMed's approach is flawed and will result in further issues.\nMindMed should have negotiated for a pivotal Phase IIb trial, to save time and money.\nMindMed's Phase IIb has a flawed dosing regimen as it tests a single dose of MM-120 rather than two doses, which was successful in multiple randomized Phase II trials.\nIn other words, Barrow is taking a significant risk by changing the dosing schedule that has been successful in Phase II randomized trials without data to support it has higher efficacy.\nThe flawed Phase IIb will result in a flawed Phase III as Barrow states that the Phase III will use one dose.\nDespite Barrow's assertion to the contrary, just because two doses are highly effective, there is no evidence that one dose will have similar efficacy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a08e0aed-5f18-4770-aea2-38dedef21fc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Clinicaltrials.gov, MindMed Earnings Call.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d43e1017-db16-422c-89ca-a16216daf73d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Flawed Approach for Phase IIb",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "339750d8-408b-423a-adf0-4108ae073e8f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 60,
      "from": 15,
      "beatId": "46c295b3-1c69-4f4e-b465-df8201aa88d9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problems by highlighting the company's lack of accountability, excessive executive compensation, and dilutive financing approach.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}